Journal
ANESTHESIA AND ANALGESIA
Volume 110, Issue 2, Pages 524-525Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1213/ANE.0b013e3181c5f069
Keywords
-
Categories
Funding
- institutional and departmental sources
Ask authors/readers for more resources
Remifentanil is a potent mu-opioid receptor agonist that produces intense analgesia. This anilidopiperidine analog of fentanyl was approved by the United States Food and Drug Administration and became commercially available in the United States in 1997. Because of its unique chemical structure, remifentanil must be reconstituted; it has a rapid onset, and because of ester hydrolysis, it has a rapid rate of degradation. Although remifentanil's package insert warns against the potential for addiction, because of its rapid rate of degradation there was little concern that health care workers would abuse this drug. Herein, we report a case of intranasal remifentanil abuse by an anesthesiology resident. (Anesth Analg 2010;110:524-5)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available